Navigation Links
Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
Date:10/3/2008

Readies R & D facilities for Ap3ana, CTI's 'personalized medicine' venture

SEATTLE, Oct. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) announced today that Christina A. Waters, Ph.D., M.B.A., most recently President and COO of a Tyr Pharma and formerly Director of Scientific Development at Genomics Institute of the Novartis Research Foundation, has been named President of CTI Europe. Based in Bresso, Italy, CTI Europe currently conducts the research and development of CTI's cancer drug pipeline.

"With her specialized background in genomics, hands on experience in integrating research and development operations, and proven strategic portfolio development capabilities, Dr. Waters, a Howard Hughes Fellow, is an excellent choice to lead the Bresso unit," said James A. Bianco, M.D., CEO of CTI. "She will bring the necessary knowledge and experience in oncology to direct Bresso's world-class scientists and bridge R&D with Translational Medicine," Bianco added.

"Leading the Bresso operation is a great opportunity as it will be a key part of the foundation on which we build Ap(3)ana. This is truly the time when we will see major advancements made in health care and we intend to be at the heart of it," Dr. Waters said.

In her new role as President of CTI Europe, Dr. Waters, will accelerate the launch of Ap(3)ana, an organization that will seek to integrate new technologies in the areas of informatics, genetics, preclinical and clinical development to advance medical treatment and predictive medicine.

Ap(3)ana is expected to combine Bresso's R & D capabilities with the advanced genomic screening of CTI's Systems Medicine subsidiary, and novel computational technologies of The Translational Genomics Research Institute. Initially, Ap(3)ana would focus these resources on establishing collaborations with biotechnology and pharmaceutical companies to improve the efficiency and likelihood of success for their clinical programs. In parallel, Ap(3)ana will seek to integrate health data from a variety of global databases to derive useful clinical insights through advanced correlations and disseminate these clinical insights to healthcare providers and communities throughout the world. Patients and clinicians would benefit from this real-time access to the best individual treatment choices.

"We are closer than ever to empowering both the clinician and the patient to make informed, individualized decisions to promote wellness," Dr. Waters said. "We expect Ap(3)ana to usher in a new era of personalized, predictive and preventative healthcare."

Dr. Waters holds a Ph.D. in Genetics from the University of California, an M.B.A. from UCLA's Anderson School of Management, and a B.S. in Biology from San Diego State University.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements, including forward-looking statements about CTI, CTI Europe and a proposed new company, Ap(3)ana, in which CTI would receive equity in exchange for the contribution of certain CTI assets upon the successful funding of Ap(3)ana. Such forward-looking statements involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect CTI Europe and the development of Ap(3)ana include, without limitation, risks associated with not successfully finalizing the proposed spin-off, the inability to successfully fund Ap(3)ana, competitive factors, challenges arising from doing business in Italy and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Specifically, the risks and uncertainties that could affect CTI include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling the product(s), and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI continues to have substantial amount of debt outstanding and the quarterly interest expense associated with the debt is significant; CTI's operating expenses continue to exceed its net revenues and CTI will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in CTI's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.282.7100

Lindsey Jesch

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
4. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
7. Former Patent Office Solicitor and Judge Joins Rothwell Figg
8. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
9. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
10. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
11. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
Breaking Biology News(10 mins):